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dataset. Prediction model variables were selected by 
evaluating the univariate Kaplan Meier curves for every 
variable at a significance level of p<0.05. Afterwards, a Cox 
proportional hazards model and logistic regression models (in 
the latter situation a model for every month) were trained. 
Furthermore, we analyzed the covariate weights for the 
regression models. Finally, all the models were validated on 
discriminative ability using the Area under the Receiver 
Operating Curve (AUC). 
 
 
 
Results: The AUC values for the prediction models are shown 
in figure 1 (blue: previous model, red: current Cox PH model, 
black: current logistic regression models). In general, the 
discriminative performance of the logistic regression model is 
higher in comparison to the newly trained Cox proportional 
hazards model or the original models, for all three outcomes. 
The covariates which changed the most over time were 
adjuvant chemo (LR, DM & OS), neo-adjuvant chemo (LR & 
OS), prescribed radiotherapy dose (LR) and pathological N-
stage (DM). 
 
 
Conclusion: Based on the current results, analyzed on the 
current dataset, we have shown that the logistic regression 
model (separate model for every time point) may perform 
better than models trying to cover the complete follow-up 
period. This may be due to the optimization capabilities, 
when training a new model for every follow-up time point, 
but might be susceptible for overfitting. From a clinical 
perspective, this could be plausible as the influence of 
variables (e.g. (neo-)adjuvant chemotherapy) may vary 
during the follow-up period and targeted outcome and could 
show how clinical and/or treatment decisions have influence 
on the patient outcome over time. Future work also involves 
handling of missing values, which is a major concern when 
merging trial datasets. 
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Purpose or Objective: To investigate long term outcome and 
predictors between two schedules of platin based 
preoperative radiochemotherapy (RTCT) 
 
Material and Methods: Patients with rectal adenoca, MRI 
based stage cT3N0-N2, were randomized into two arms: 
1) PLAFUR: RT= 50.4 Gy; Concurrent chemotherapy (CT)= 
CDDP 60 mg m2 (days 1-29) + 5FU continuous infusion in 96 h 
(days 1-4 and 29-32) 
2) TOMOX-RT: RT=50.4 Gy; CT= Tomudex 3 mg / m2 + 
oxaliplatin 130 mg / m2 (days 1, 19 and 38). 
Restaging at 6-8 weeks after the end of RTCT, followed by 
surgery in 1-2 weeks. 
Adjuvant CT was recommended in ypN1-2. 
Local control (LC), metastases-free survival (MFS), disease-
free survival (DFS) and overall survival (OS) were analyzed. 
Predictive endpoints of clinical outcome were tested by 
univariate and multivariate analysis. The investigated 
variables were: (i) patients (age, sex), (ii) therapy (RTCT 
schedule, adjuvant CT, surgery type, colostomy), (iii) tumor 
related (cT, cN, ypT, ycN, TRG grade, site of primary T). 
 
Results: From 2002 to 2005, 164 patients were enrolled (M: F 
= 104: 60); 83 were randomized to PLAFUR and 81 to TOMOX-
RT. The median follow-up was 120.2 months (5.8-152.5).  
The 10-years rates of the efficacy endpoints, per arm, were 
as follows: LC: PLAFUR= 89.2% , TOMOX-RT= 96.3% 
(p=0.0757); MFS: PLAFUR= 81.9% , TOMOX-RT= 81.5% 
(p=0.987) ; DFS: PLAFUR= 78.3% , TOMOX-RT= 77.8% 
(p=0.982); OS: PLAFUR =50%, TOMOX-RT= 50% (p=0.918) 
TOMOX-RT showed a non-significantly higher rate of ypT0 
compared to PLAFUR: 35.8% vs 24.1% (p = 0.102), 
respectively. 
Sphincter-saving surgery procedure was applied in: PLAFUR= 
87.9%, TOMOX-RT= 86.4%. 
Grade 3-4 acute toxicity occurred in: 7.1% in the PLAFUR arm 
vs 16.4% in the TOMOX-RT arm.  
Confirmed predictors of outcome were found: 
- For LC: at univariate analisys= ypT; ypN, TRG Grade; at 
multivariate analysis= TRG Grade (p = 0.0126) 
- For MFS: at univariate analisys= age ypT, ypN and TRG 
Grade; at multivariate analysis= TRG Grade (p = 0.0255) 
- For DFS: at univariate analisys= age ypT, ypN and TRG 
Grade; at multivariate analysis= TRG Grade (p = 0.0224) 
- For OS: at univariate analisys= age ypT, ypN and TRG Grade; 
at multivariate analysis= no predictor was significantly 
associated. 
 
Conclusion: The TOMOX-RT schedule allowed higher non-
significant local control, and comparable clinical outcome to 
the compared schedule. Moreover the ypT downstaging was 
significantly improved. Acute toxicity was comparable 
between arms. 
The TRG Grade was a good independent variable predicting 
LC, MFS and DFS, but not OS.  
 
 
